Meta-Analysis of Data from Trials of Thrombolytic Therapy in Acute Ischemic Stroke

  • J. Wardlaw
Conference paper


The most efficient method of evaluating treatment, particularly where the effect is modest rather than large and instantly obvious, is the randomized controlled trial (RCT). Many treatments have modest benefits that must be weighed carefully against their risks, so treatment effect can only be measured accurately in a RCT. This is particularly true for thrombolysis for acute ischemic stroke where both the hoped-for beneficial effects (reperfusion and clinical improvement) and the feared adverse effects (cerebral hemorrhage and clinical deterioration) mimic the natural history of ischemic stroke [1]


Acute Stroke Acute Ischemic Stroke Thrombolytic Therapy Individual Patient Data Recombinant Tissue Plasminogen Activator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bamford J, Sandercock PAG, Dennis M, Burn J, Warlow CP (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337: 1521–1526PubMedCrossRefGoogle Scholar
  2. 2.
    Cochrane AL (1972) Effectiveness and efficiency: random reflections on health services. Nuffield Provincial Hospitals Trust, LondonGoogle Scholar
  3. 3.
    Peto R (1987) Why do we need systematic overviews of randomised trials? Stat Med 6: 233–240PubMedCrossRefGoogle Scholar
  4. 4.
    Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH (1985) Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomised controlled trials. Eur Heart J 6: 556–585PubMedGoogle Scholar
  5. 5.
    MacMahon S, Collins R, Peto R, Koster RW, Yusuf S (1988) Effects of prophylactic lidocaine in suspected acute myocardial infarction. JAMA 260: 1910–1916PubMedCrossRefGoogle Scholar
  6. 6.
    ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of acute myocardial infarction. Lancet 2: 349–360Google Scholar
  7. 7.
    Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC (1992) A comparison of results of meta-analyses of randomised control trials and recommendations of clinical experts. JAMA 268: 240–248PubMedCrossRefGoogle Scholar
  8. 8.
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337: 867–872PubMedCrossRefGoogle Scholar
  9. 9.
    Stewart LA, Parmar MKB (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341: 418–422PubMedCrossRefGoogle Scholar
  10. 10.
    Wardlaw JM, Warlow CP (1992) Thrombolysis in acute ischaemic stroke: does it work? Stroke 23: 1826–1839PubMedCrossRefGoogle Scholar
  11. 11.
    Meyer JS, Gilroy J, Barnhart MI, Johnson JF (1963) Therapeutic thrombolysis in cerebral thromboembolism. Neurology 13: 927–937PubMedGoogle Scholar
  12. 12.
    Meyer JS, Gilroy J, Barnhart MI, Johnson JF (1964) Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 189: 373PubMedCrossRefGoogle Scholar
  13. 13.
    Ohtomo E, Araki G, Itoh E, Tougi H, Matuda T, Atarashi J (1985) Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Clin Eval 13: 711–751Google Scholar
  14. 14.
    Abe T, Kazama M, Naito I, Ueda M, Tanaka T, Higuchi H, Saso S, Kariyone S, Yoshimura M (1981) Clinical evaluation for efficacy of tissue cultured urokinase ( TCUK) on cerebral thrombosis by means of multi-center double-blind study. Blood Vessels 12: 321–341CrossRefGoogle Scholar
  15. 15.
    Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976–982PubMedGoogle Scholar
  16. 16.
    Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group (1993) Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double blind trial. In: del Zoppo GJ, Mori E, Hacke W (eds) Thrombolytic therapy in acute ischaemic stroke II. Springer, Berlin, pp 59–65Google Scholar
  17. 17.
    Atarashi J, Ohtomo E, Araki G, Itoh E, Togi H, Matsuda T (1985) Clinical utility of urokinase in the treatment of acute stage cerebral thrombosis: multi-centre double blind study in comparison with placebo. Clin Eval 13: 659–709Google Scholar
  18. 18.
    Naito I (1984) Basic and clinical studies on oral urokinase and lysyl-plasminogen. New means of thrombolytic therapy for cerebral thrombosis (in Japanese). Rinsho Ketsueki 25: 1027–1035PubMedGoogle Scholar
  19. 19.
    Haley EC Jr, Brott TG, Sheppard GL, Barsan W, Broderick J, Marler JR, Kongable GL, Spilker J, Massey S, Hansen CA, Torner JC, for the TPA Bridging Study Group (1993) Pilot randomised trial of tissue plasminogen activator in acute ischaemic stroke. Stroke 24: 1000–1004CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • J. Wardlaw
    • 1
  1. 1.Department of Clinical Neurosciences, Bramwell-Dott BuildingWestern General HospitalEdinburghUK

Personalised recommendations